These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31558802)

  • 1. Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer.
    Joseph C; Al-Izzi S; Alsaleem M; Kurozumi S; Toss MS; Arshad M; Goh FQ; Alshankyty IM; Aleskandarany MA; Ali S; Ellis IO; Mongan NP; Green AR; Rakha EA
    Br J Cancer; 2019 Oct; 121(9):776-785. PubMed ID: 31558802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.
    Aleskandarany MA; Abduljabbar R; Ashankyty I; Elmouna A; Jerjees D; Ali S; Buluwela L; Diez-Rodriguez M; Caldas C; Green AR; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2016 Sep; 159(2):215-27. PubMed ID: 27514395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.
    Joseph C; Macnamara O; Craze M; Russell R; Provenzano E; Nolan CC; Diez-Rodriguez M; Sonbul SN; Aleskandarany MA; Green AR; Rakha EA; Ellis IO; Mukherjee A
    Br J Cancer; 2018 Apr; 118(8):1142-1151. PubMed ID: 29588513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.
    Alfarsi LH; Ansari RE; Craze ML; Toss MS; Masisi B; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2019 Dec; 178(3):535-544. PubMed ID: 31471836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer.
    Abduljabbar R; Al-Kaabi MM; Negm OH; Jerjees D; Muftah AA; Mukherjee A; Lai CF; Buluwela L; Ali S; Tighe PJ; Green A; Ellis I; Rakha E
    Breast Cancer Res Treat; 2015 Apr; 150(3):511-22. PubMed ID: 25794775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DC-SCRIPT: nuclear receptor modulation and prognostic significance in primary breast cancer.
    Ansems M; Hontelez S; Looman MW; Karthaus N; Bult P; Bonenkamp JJ; Jansen JH; Sweep FC; Span PN; Adema GJ
    J Natl Cancer Inst; 2010 Jan; 102(1):54-68. PubMed ID: 20008677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
    Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
    Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High nuclear MSK1 is associated with longer survival in breast cancer patients.
    Pu X; Storr SJ; Ahmad NS; Rakha EA; Green AR; Ellis IO; Martin SG
    J Cancer Res Clin Oncol; 2018 Mar; 144(3):509-517. PubMed ID: 29327245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
    Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
    Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
    Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
    Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
    Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
    Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
    Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.
    Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Aishima S; Morita M; Kakeji Y; Maehara Y
    Ann Surg Oncol; 2012 Apr; 19(4):1145-52. PubMed ID: 21984487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast.
    Narbe U; Sjöström M; Forsare C; Bendahl PO; Alkner S; Leeb-Lundberg LMF; Lövgren K; Rydén L; Ingvar C; Fernö M
    Breast Cancer Res Treat; 2019 Jun; 175(2):305-316. PubMed ID: 30796653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival.
    Joseph C; Alsaleem M; Orah N; Narasimha PL; Miligy IM; Kurozumi S; Ellis IO; Mongan NP; Green AR; Rakha EA
    Breast Cancer Res Treat; 2020 Jul; 182(2):267-282. PubMed ID: 32445177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer.
    Aljohani AI; Joseph C; Kurozumi S; Mohammed OJ; Miligy IM; Green AR; Rakha EA
    Breast Cancer Res Treat; 2020 Jun; 181(3):541-551. PubMed ID: 32350677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.
    Alfarsi LH; Elansari R; Toss MS; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2019 Jan; 173(1):93-102. PubMed ID: 30306428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOXA1 is an independent prognostic marker for ER-positive breast cancer.
    Mehta RJ; Jain RK; Leung S; Choo J; Nielsen T; Huntsman D; Nakshatri H; Badve S
    Breast Cancer Res Treat; 2012 Feb; 131(3):881-90. PubMed ID: 21503684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer.
    Kariri YA; Joseph C; Kurozumi S; Toss MS; Alsaleem M; Raafat S; Mongan NP; Aleskandarany MA; Green AR; Rakha EA
    Breast Cancer Res Treat; 2020 Jan; 179(2):349-357. PubMed ID: 31679074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.